Sorin Biomedica's cardiology sales ride healthcare budget cuts
This article was originally published in Clinica
Executive Summary
Sorin Biomedica's cardiology sales rose 6.2% to Lit 453 billion ($273 million) in 1994, according to the company's annual report. They were up 11% on a comparative basis. According to the sales breakdown, turnover by the diagnostics division remained virtually static - up just 0.4% at Lit 217 billion, while haemodialysis sales rose 8.4% to Lit 167 billion.
You may also be interested in...
Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking
Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip